3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Colorectal Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
39
Gemcitabine
30
Nivolumab
15
Cetuximab
13
Carboplatin
13
Cyclophosphamide
12
Cisplatin
12
Irinotecan
10
Docetaxel
10
130-nm albumin-bound paclitaxel
10
Trastuzumab
8
Magnetic Resonance Spectroscopy
8
fludarabine
7
aldesleukin
7
Paclitaxel
7
Drug Therapy
7
Bevacizumab
7
Taxes
6
Specimen Handling
6
Fluorouracil
6
Capecitabine
6
Albumin-Bound Paclitaxel
6
sargramostim
5
Pemetrexed
5
Oxaliplatin
5
Ipilimumab
5
spartalizumab
4
durvalumab
4
Standard of Care
4
Radiotherapy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
naporafenib
×
Thoracic
×
Clear all
NCT05907304
2026-02-27
SEACRAFT-1
Erasca, Inc.
Phase 1
Active not recruiting
86 enrolled